Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

St Galler Kantonalbank Ag / Equity Bottom-Up

St. Galler Kantonalbank AG is a Swiss regional bank.  The Bank offers retail and commercial banking as well as private and institutional banking.  SGKB also provides asset management and financial planning services.  The Bank offers its services in the Canton of St. Gall through a network of branches.

<ul>
 <li>
Defensive Regional Banking Powerhouse with Cantonal Guarantee: St. Galler Kantonalbank AG (SGKN SW) commands a dominant retail and commercial banking franchise in Eastern Switzerland, supported by a 51.0% majority ownership and statutory deficiency guarantee from the Canton of St. Gallen. This sovereign backing drives ultra-low funding costs, high deposit stickiness, and a pristine balance sheet.</li>
 <li>
Strong Earnings Quality and Net Margin Expansion: Despite changing interest rate cycles, SGKB generated a record net profit of CHF 226.98M in 2025, with net margins widening to 26.15%. A 3-year EPS CAGR of 7.29% and 3-year net income CAGR of 7.30% demonstrate superior operating efficiency and disciplined credit risk underwriting.</li>
 <li>
Predictable Capital Return with 5/5 Price Momentum: Trading at CHF 703.00, SGKN offers an attractive 2.82% dividend yield supported by an unbroken history of progressive payouts, reaching CHF 20.00 per share in 2026. SGKB trades at a fair valuation of ~18.0x P/E and ~1.3x P/B, justified by high capital strength, a dual-pillar retail/wealth model, and top-tier momentum.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Defensive Regional Banking Powerhouse with Cantonal Guarantee: St. Galler Kantonalbank AG (SGKN SW) commands a dominant retail and commercial banking franchise in Eastern Switzerland, supported by a 51.0% majority ownership and statutory deficiency guarantee from the Canton of St. Gallen. This sovereign backing drives ultra-low funding costs, high deposit stickiness, and a pristine balance sheet.
  
Strong Earnings Quality and Net Margin Expansion: Despite changing interest rate cycles, SGKB generated a record net profit of CHF 226.98M in 2025, with net margins widening to 26.15%. A 3-year EPS CAGR of 7.29% and 3-year net income CAGR of 7.30% demonstrate superior operating efficiency and disciplined credit risk underwriting.
  
Predictable Capital Return with 5/5 Price Momentum: Trading at CHF 703.00, SGKN offers an attractive 2.82% dividend yield supported by an unbroken history of progressive payouts, reaching CHF 20.00 per share in 2026. SGKB trades at a fair valuation of ~18.0x P/E and ~1.3x P/B, justified by high capital strength, a dual-pillar retail/wealth model, and top-tier momentum.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: St Galler Kantonalbank Ag (SGKN SW) - Oct 2026

Asian Hedge Fund Manager, Long Short Equity, Macro

David Mudd

Cross Asset Strategy

<ul>
<li>DC company share prices are rolling over, foreshadowing increasing pressure on their hyperscaler customers.  Since the July swoon in semiconductor stocks, the DC sector has underperformed both hyperscalers and semiconductors.</li>
<li>DC players face strong headwinds on multiple fronts, including high leverage/circular financing, supply chain delays, public opposition, and questions about aggressive forecasts of future compute demand.</li>
<li>Leverage is the most prominent risk in the DC sector, with questions looming about completion dates and customers' ability to meet their contracted offtake agreements.</li>
</ul>


DC company share prices are rolling over, foreshadowing increasing pressure on their hyperscaler customers.  Since the July swoon in semiconductor stocks, the DC sector has underperformed both hyperscalers and semiconductors.
DC players face strong headwinds on multiple fronts, including high leverage/circular financing, supply chain delays, public opposition, and questions about aggressive forecasts of future compute demand.
Leverage is the most prominent risk in the DC sector, with questions looming about completion dates and customers' ability to meet their contracted offtake agreements.


DATA CENTER SECTOR: From the Tip of the Spear to Canary in the Coal Mine

Director, Sentiment Matters

Lars Kreckel

Director

The mood of the market, mapped and decoded

Sentiment Matters

Investor sentiment is the overall mood of investors - how bullish or bearish they are on a market or asset.

Sentiment is part of every investor’s investment process. Whether for macro investors, stock pickers, or thematic investors, it matters whether a position is consensus or contrarian.

<ul>
<li>
Buy Side Sentiment Tracker: we aggregate asset-allocation views from 54 top asset managers across 73 assets, based on 1,400+ individual views.</li>
<li>
Bullish, but not extreme: Risk appetite is high and rising, yet equity downgrades and resilient sovereign demand show the Buy Side is far from universally risk-on.</li>
<li>
Max Contrarian: Infrastructure, Industrial Metals and Gold are most popular; Swiss Franc, Cash and Consumer Staples are least popular.</li>
</ul>



Buy Side Sentiment Tracker: we aggregate asset-allocation views from 54 top asset managers across 73 assets, based on 1,400+ individual views.

Bullish, but not extreme: Risk appetite is high and rising, yet equity downgrades and resilient sovereign demand show the Buy Side is far from universally risk-on.

Max Contrarian: Infrastructure, Industrial Metals and Gold are most popular; Swiss Franc, Cash and Consumer Staples are least popular.


Sentiment Matters: Buy Side Sentiment Tracker - October 2026

Research from Quam Securities, Quam Securities

Quam Securities Research

Research from Quam Securities

Quam Securities

Since its inception in 1986, Quam Securities Limited (Quam Securities) has grown to become one of the few mid-tier securities brokerages in Hong Kong with global execution capabilities for both private and institutional clients. It boasts a well-established network in Greater China including Taiwan and in major world markets through the Global Alliance Partners (GAP). Quam Securities is well-positioned not only to harness and drive business within the China Tonghai International Financial Limited but also between China and the world markets.

<ul><li>Hong Kong bourse demonstrated feeble rebound momentum in lack of support from southbound funds.</li><li>Sentiment was supported by weaker-than-expected US employment data, which reduced expectations for another Fed rate hike this month, while Treasury yields eased.</li><li>Hong Kong retail sales rose 2.9% year-on-year in August, the fastest growth in three months.</li></ul>

Hong Kong bourse demonstrated feeble rebound momentum in lack of support from southbound funds.Sentiment was supported by weaker-than-expected US employment data, which reduced expectations for another Fed rate hike this month, while Treasury yields eased.Hong Kong retail sales rose 2.9% year-on-year in August, the fastest growth in three months.

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent protected prescription medicine and generic pharmaceuticals and biosimilars.

<ul><li>Novartis is making another major bet on Chinese biotechnology, agreeing to pay Abogen Biosciences $575 million upfront for worldwide rights to its lead drug candidate, ABO2203, alongside options on additional medicines from Abogen’s RNA platform.</li><li>If every option is exercised and development milestones are achieved, total payments could reach roughly $7.8 billion.</li><li>That headline number is eye-catching, but the bigger story extends far beyond a single experimental drug.</li></ul>

Novartis is making another major bet on Chinese biotechnology, agreeing to pay Abogen Biosciences $575 million upfront for worldwide rights to its lead drug candidate, ABO2203, alongside options on additional medicines from Abogen’s RNA platform.If every option is exercised and development milestones are achieved, total payments could reach roughly $7.8 billion.That headline number is eye-catching, but the bigger story extends far beyond a single experimental drug.

Novartis Bets $7.8 Billion On Chinese Biotech—Could This Be Its Next Blockbuster Engine?